Imatinib Sandoz (Imatinib)

Imatinib acts on malignant cells driven by BCR‑ABL, c‑KIT or PDGFR tyrosine‑kinase pathways.

• Chronic myeloid leukemia: blocks BCR‑ABL signaling to achieve disease control and prolong survival.
• Acute lymphoblastic leukemia: inhibits tyrosine‑kinase activity to reduce leukemic proliferation.
• Gastrointestinal stromal tumor: targets c‑KIT and PDGFR to limit tumor growth and improve progression‑free survival.

• Imatinib selectively inhibits the ATP‑binding site of BCR‑ABL, c‑KIT and platelet‑derived growth factor receptors (PDGFR). By preventing phosphorylation of these tyrosine kinases, the drug disrupts downstream signaling pathways that drive uncontrolled cell division, thereby inducing apoptosis or growth arrest in malignant cells that depend on these kinases for survival.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Edema: peripheral swelling, often of the ankles.
• Fatigue: generalized tiredness affecting daily activities.
• Diarrhea: loose stools that may be intermittent.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or liver injury requiring monitoring.
• Severe neutropenia: marked reduction in white blood cells increasing infection risk.
• Cardiac failure: reduced cardiac function presenting as dyspnea or edema.

Before initiating therapy, clinicians should assess baseline organ function and monitor patients regularly.

• Monitor blood counts: check complete blood count weekly during the first month.
• Assess liver function: perform hepatic panel before treatment and periodically thereafter.
• Evaluate cardiac status: baseline ECG and echocardiogram for patients with pre‑existing heart disease.
• Pregnancy considerations: avoid use unless potential benefit justifies risk to the fetus.
• Review concomitant medications: adjust doses of drugs metabolized by CYP3A4.
• Store at room temperature: keep in the original container, protect from moisture and light.

Imatinib may interact with several medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations and toxicity.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy by lowering drug levels.
• Antacids containing aluminum or magnesium: can impair absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• Diuretics (e.g., furosemide): may increase risk of fluid retention and edema.